InnoCare Pharma (SHA:688428) received approval from China's Center for Drug Evaluation (CDE) to conduct a Phase III trial of its BCL2 inhibitor, ICP-248 (Mesutoclax), in combination with BTK inhibitor orelabrutinib for first-line treatment of CLL/SLL, according to a Tuesday filing with the Shanghai bourse.
The therapy aims to enhance remission and reduce resistance mutations. Previous Phase II results showed promising efficacy and safety.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。